Four years after Wegovy’s original approval, the population-level numbers are starting to move — and a new Gallup poll released in July 2026 puts real figures behind what’s been mostly anecdotal until now. About 11% of American adults are currently taking a GLP-1 medication for weight loss, up sharply from 8% in 2025 and just 3% in 2024. Over the same stretch, the national obesity rate has fallen to 36.4%, down from a record 39.9% in 2022 — the year after Wegovy’s first approval. Correlation isn’t proof of causation at a population level, but the timing and the direction are both hard to ignore.
The Numbers, In Context
Gallup’s web-based survey of 5,065 U.S. adults, conducted in late May and early June 2026 through its probability-based Gallup Panel across all 50 states and D.C., found that current GLP-1 use has nearly quadrupled in two years — from 3% in 2024 to 11% by mid-2026. Looking at ever-use rather than current use, the number is even larger: 15% of American adults report having used a GLP-1 medication for weight loss at some point, a nine-percentage-point jump over the same period. Awareness has climbed just as fast — 91% of respondents in 2026 knew GLP-1 drugs could treat weight loss, up from 80% just two years earlier. This is no longer a niche or unfamiliar category of medicine for most Americans.
What Changed to Make This Possible
The growth curve tracks closely with a string of access-expanding developments across 2025 and 2026: injectable and then oral formulations reaching the market, new manufacturer savings programs, expanded insurance coverage in many commercial plans, and — as of July 1, 2026 — the Medicare GLP-1 Bridge demonstration offering $50-a-month coverage to millions of eligible seniors. Pricing has also become more competitive as the field has grown from a single manufacturer to multiple approved options across Novo Nordisk and Eli Lilly, including lower self-pay entry points on newer products like Foundayo. None of these developments alone explains an 11% adoption rate, but together they describe a drug class that’s moved from expensive and hard to access to genuinely mainstream in a remarkably short window.
A Real Caveat Worth Naming
It’s tempting to draw a straight line from rising GLP-1 use to the falling obesity rate, and the timing is genuinely suggestive — the obesity rate peaked the year after Wegovy’s approval and has declined as adoption has grown. But population-level obesity statistics respond to many inputs beyond any single drug class: changes in diagnostic and self-reporting methodology, economic conditions, food environment shifts, and general public health trends all move the number too. Gallup’s data shows a strong correlation and a genuinely plausible mechanism, not an isolated, controlled experiment proving GLP-1 adoption alone caused the decline. Public health researchers will likely spend years untangling exactly how much of the shift is attributable to the drugs themselves.
Frequently Asked Questions
Does this poll prove GLP-1 drugs caused the obesity rate decline?
Not on its own. It shows a strong correlation between rising GLP-1 adoption and falling obesity rates over the same period, which is a genuinely meaningful signal, but establishing direct causation at a population level requires more controlled research than a single survey can provide.
How was this survey conducted?
Gallup surveyed 5,065 U.S. adults from May 28 to June 5, 2026, using its probability-based Gallup Panel, covering all 50 states and the District of Columbia.
What’s driving the growth in GLP-1 use?
Expanding drug options (injectable and oral formulations from multiple manufacturers), broader insurance and Medicare coverage, growing public awareness, and increasingly competitive pricing have all contributed to adoption climbing from 3% to 11% of U.S. adults between 2024 and 2026.
This article is for educational purposes only and summarizes publicly available survey and public health data. It is not medical advice.